Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...